Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aton (ALTAO.PA)
Strasbourg, FR
Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinical and clinical services, and the creation of monoclonal antibodies. Additionally, Aton manufactures laboratory equipment, designs and produces various medical devices—including specialized surgical instruments powered by Stemcis technology—and supplies human tissues.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -9.23% | -29.76% | +90.32% | +68.57% | +63.89% | +37.21% | -77.57% | -94.22% | -98.60% | -99.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+24,502.6% ★ Q4'23: +30.4% (vs Q4'21)
-
EPS growth Biotechnology: +29.7%-2,242.9% Q4'23: -1,740.0% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%+1,746.9% Q4'23: +0.0% (vs Q4'21)
-
EBIT margin Biotechnology: +0.0%-3,485.5% Q4'23: -3,485.5% (vs Q4'21)
-
ROIC Biotechnology: -16.1%— Q4'23: +1,108.0% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+40.0% Q4'23: +44.9% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.18× Q4'23: -3.59× (vs Q4'21)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ayikoele Atayi | GM & Chair of the Board of Directors | 47.5K | female |
| Hadrien Lanvin | Deputy CEO & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALTAO.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
